TY - JOUR T1 - Temporal Dynamics of the Adult Female Lower Urinary Tract Microbiota JF - medRxiv DO - 10.1101/2020.03.06.20032193 SP - 2020.03.06.20032193 AU - Travis K. Price AU - Birte Wolff AU - Thomas Halverson AU - Roberto Limeira AU - Linda Brubaker AU - Qunfeng Dong AU - Elizabeth R. Mueller AU - Alan J. Wolfe Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/03/10/2020.03.06.20032193.abstract N2 - Temporal dynamics of certain human microbiotas have been described in longitudinal studies; variability often relates to modifiable factors or behaviors. Early studies of the urinary microbiota preferentially used samples obtained by transurethral catheterization to minimize vulvo-vaginal microbial contributions. Whereas voided specimens are preferred for longitudinal studies, the few studies that reported longitudinal data were limited to women with lower urinary tract (LUT) symptoms, due to ease of accessing a clinical population for sampling and the impracticality and risk of collecting repeated catheterized urine specimens in a non-clinical population. Here, we studied the microbiota of the LUT of non-symptomatic, pre-menopausal women using mid-stream voided urine (MSU) specimens to investigate relationships between microbial dynamics and personal factors. Using 16S rRNA gene sequencing and a metaculturomics method called Expanded Quantitative Urine Culture (EQUC), we characterized the microbiotas of MSU and peri-urethral swab specimens collected daily for approximately three months from a small cohort of adult women. Participants were screened for eligibility, including ability to self-collect paired urogenital specimens prior to enrollment. In this population, we found that measures of microbial dynamics related to specific participant-reported factors, particularly menstruation and vaginal intercourse. Further investigation of the trends revealed differences in composition and diversity of LUT microbiotas within and across participants. These data, in combination with previous studies showing relationships between the LUT microbiota and LUT symptoms, suggest that personal factors relating to the genitourinary system may be an important consideration in the etiology, prevention, and/or treatment of LUT disorders.IMPORTANCE Following the discovery of the collective human urinary microbiota, important knowledge gaps remain, including the stability and variability of this microbial niche over time. Initial urinary studies preferentially utilized samples obtained by transurethral catheterization to minimize contribution from vulvo-vaginal microbes. However, catheterization has the potential to alter the urinary microbiota; therefore, voided specimens are preferred for longitudinal studies. In this report, we describe the microbial findings obtained by daily assessment over three months in a small cohort of adult women. Similar to vaginal microbiotas, we found that lower urinary tract (LUT) microbiotas are dynamic with changes relating to several factors, particularly menstruation and vaginal intercourse. Our study shows that LUT microbiotas are both dynamic and resilient. It also offers novel opportunities to target LUT microbiotas for preventative or therapeutic means, through risk and/or protective factor modification.Competing Interest StatementDr. Mueller discloses research support from NIH and Astellas Scientific and Medical Affairs, membership on the Advisory Boards of Boston Scientific, Ferring, and UroCure, UpToDate Royalties, and Butler Snow/Ethicon Legal Review Up, Dr. Brubaker discloses research funding from NIH and editorial stipends from Female Pelvic Medicine and Reconstructive Surgery, UpToDate and JAMA. Dr. Wolfe discloses research support from NIH, the DOD, Astellas Scientific and Medical Affairs and Kimberly Clark Corporation. The remaining authors (Price, Wolff, Halverson, Limeira, Dong) report no disclosures.Funding StatementWe acknowledge funding from NIH (R01 DK104718 awarded to AJW and LB). The funders did not play a part in the design or conduct of the study.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request ER -